1-phenyl-2-decanoylamino-3-morpholino-1-propanol has been researched along with 1-deoxynojirimycin in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, A; Radin, NS; Shayman, JA | 1 |
| Bieberich, E; Freischütz, B; Suzuki, M; Yu, RK | 1 |
| Butters, TD; Dwek, RA; Jeyakumar, M; Platt, FM | 1 |
| Butters, TD; Callaghan, R; Dwek, RA; Norris-Cervetto, E; Platt, FM | 1 |
| Garner, B; Gelissen, I; Glaros, EN; Jessup, W; Kim, WS; Quinn, CM; Wong, J | 1 |
| Fujisawa, T; Hayakawa, T; Ishii, K; Ishitsuka, R; Ito, K; Kobayashi, T; Makino, A; Matsuo, H; Murate, M; Suzuki, M; Suzuki, Y | 1 |
| Bergmann, M; Gabius, HJ; Kopitz, J | 1 |
| Chen, CL; Chen, TY; Chen, YP; Cheng, YL; Hsieh, CY; Huang, WC; Lin, CF; Lin, CM; Lin, YS; Lu, PJ; Tsai, CC; Tsao, CW; Tseng, PC; Wang, CY; Wang, SH | 1 |
| Barrier, L; Ingrand, S; Noel, A | 1 |
1 review(s) available for 1-phenyl-2-decanoylamino-3-morpholino-1-propanol and 1-deoxynojirimycin
| Article | Year |
|---|---|
Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
Topics: 1-Deoxynojirimycin; Animals; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Disease Models, Animal; G(M2) Ganglioside; Gangliosides; Glucosylceramides; Glucosyltransferases; Glycosphingolipids; Humans; Lysosomal Storage Diseases; Lysosomes; Mice; Models, Biological; Models, Chemical; Morpholines; Sandhoff Disease; Tay-Sachs Disease; Treatment Outcome | 2002 |
8 other study(ies) available for 1-phenyl-2-decanoylamino-3-morpholino-1-propanol and 1-deoxynojirimycin
| Article | Year |
|---|---|
Induction of glucosylceramide synthase by synthase inhibitors and ceramide.
Topics: 1-Deoxynojirimycin; Animals; Biological Transport; Cell Membrane; Cells, Cultured; Ceramides; Dogs; Enzyme Inhibitors; Glucosyltransferases; Morpholines; Sphingomyelin Phosphodiesterase | 1996 |
Differential effects of glycolipid biosynthesis inhibitors on ceramide-induced cell death in neuroblastoma cells.
Topics: 1-Deoxynojirimycin; Animals; Apoptosis; Brain Neoplasms; Cell Death; Cell Division; Ceramides; Enzyme Inhibitors; Gaucher Disease; Glucosylceramides; Glucosyltransferases; Glycolipids; Mice; Morpholines; Neuroblastoma; Rats; Tumor Cells, Cultured | 1999 |
Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells.
Topics: 1-Deoxynojirimycin; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Ceramides; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; Glucosamine; Glucosylceramides; Glucosyltransferases; Glycolipids; Humans; Imino Sugars; Lipids; Morpholines; Quinolines; Time Factors; Vinblastine | 2004 |
Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apolipoprotein A-I pathway: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator.
Topics: 1-Deoxynojirimycin; Antigens, CD; Apolipoprotein A-I; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biotinylation; Blotting, Western; Cell Line; Cell Membrane; Cholesterol; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fibroblasts; Glycosphingolipids; Humans; Lactosylceramides; Lipoproteins, LDL; Monocytes; Morpholines; Phospholipids; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Up-Regulation | 2005 |
D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol alters cellular cholesterol homeostasis by modulating the endosome lipid domains.
Topics: 1-Deoxynojirimycin; 4-Chloro-7-nitrobenzofurazan; Cells, Cultured; Ceramides; Cholesterol; Endosomes; Enzyme Activation; Fibroblasts; Glucosyltransferases; Homeostasis; Humans; Lipase; Lysophospholipids; Membrane Microdomains; Monoglycerides; Morpholines; Neuroblastoma; Paclitaxel; Stereoisomerism; Sterol Esterase | 2006 |
How adhesion/growth-regulatory galectins-1 and -3 attain cell specificity: case study defining their target on neuroblastoma cells (SK-N-MC) and marked affinity regulation by affecting microdomain organization of the membrane.
Topics: 1-Deoxynojirimycin; 2-Hydroxypropyl-beta-cyclodextrin; Anti-Bacterial Agents; beta-Cyclodextrins; Cell Adhesion; Cell Membrane; Enzyme Inhibitors; Excipients; Filipin; G(M1) Ganglioside; Galectin 1; Galectin 3; Glycoside Hydrolase Inhibitors; Humans; Membrane Microdomains; Morpholines; Neuroblastoma; Tumor Cells, Cultured | 2010 |
Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis.
Topics: 1-Deoxynojirimycin; Animals; Apoptosis; Cell Line, Tumor; Ceramides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Genes, abl; Glucosyltransferases; Glycogen Synthase Kinase 3; Humans; Immunoglobulin G; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melphalan; Mice; Mice, SCID; Morpholines; Mutation; Neoplasms, Experimental; Pyrimidines; Transplantation, Heterologous | 2011 |
Anti-amyloidogenic effects of glycosphingolipid synthesis inhibitors occur independently of ganglioside alterations.
Topics: 1-Deoxynojirimycin; Amyloid beta-Peptides; Cell Line, Tumor; Enzyme Inhibitors; Gangliosides; Humans; Morpholines; Neurons | 2016 |